Опубликована: Окт. 10, 2023
O Lúpus Eritematoso
Expert Review of Clinical Immunology, Год журнала: 2023, Номер 19(7), С. 771 - 784
Опубликована: Апрель 28, 2023
With a growing knowledge of Inborn errors immunity (IEI), immunological profiling and genetic predisposition to IEI phenocopies have been developed in recent years.Here we summarized the correlation between various pathogen invasions, autoantibody profiles, corresponding clinical features context patients with phenocopies. It has extensively evident that anti-cytokine autoantibodies underly impaired anti-pathogen immune responses lead broad unregulated inflammation tissue damage. Several hypotheses production are here, including defective negative selection autoreactive T cells, abnormal germinal center formation, molecular mimicry, HLA class II allele region, lack auto-reactive lymphocyte apoptosis, other possible hypotheses.Phenocopies associated increasingly recognized as one causes acquired immunodeficiency susceptibility certain infections, especially facing current challenge COVID-19 pandemic. By investigating clinical, genetic, pathogenesis profiles pathogens' susceptibilities, could better understand autoantibodies, for those underlie life-threatening SARS-CoV-2.
Язык: Английский
Процитировано
2
Journal of Medical Case Reports, Год журнала: 2024, Номер 18(1)
Опубликована: Июнь 19, 2024
Abstract Background Patients with coronavirus disease 2019 have a high incidence of thrombosis that decreases after recovery. When is accompanied by diseases prone to thrombosis, risk post-infection thrombotic events may increase. Case presentation We report case digital ischemic gangrene in 24-year-old Chinese female systemic lupus erythematosus recovery from 2019. The pathogenesis was related clinical characteristics erythematosus, hypercoagulability caused 2019, and second-hit due viral infection. Conclusion autoimmune should remain alert system disorders induced severe acute respiratory syndrome 2 other viruses. Treatment for these patients be strictly standardized, appropriate anticoagulation methods selected prevent thrombosis.
Язык: Английский
Процитировано
0
International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(15), С. 8278 - 8278
Опубликована: Июль 29, 2024
Systemic lupus erythematosus (SLE) patients have an increased risk of infections and infection-related mortality. Therefore, during the global SARS-CoV-2 pandemic, SLE were particularly vulnerable to infections. Also, compared other patients, seem develop more severe manifestations coronavirus disease 2019 (COVID-19), with higher rates hospitalization, invasive ventilation requirements, or death. This study evaluated immune parameters after infection in patients. We analyzed subpopulations peripheral blood cells collected from renal manifestation (lupus nephritis, LN). LN divided into two subgroups: those unexposed (LN CoV-2(−)) who had confirmed COVID-19 (LN-CoV-2(+)) six months earlier. basic T cells, B monocytes, dendritic (DCs), serum cytokines using flow cytometry. All data a healthy control group without medical history. characterized by decreased percentage helper (Th) cytotoxic (Tc) regardless infection. CoV-2(+) regulatory (Tregs) plasmablasts (PBs) lower non-switched memory (NSM) CoV-2(−) controls (HC CoV-2(−)). total monocytes HC CoV-2(−). classical intermediate than IL-6 levels CoV-2(−), while IL-10. are disturbances blood’s immunological parameters. However, influences B-cell monocyte compartments.
Язык: Английский
Процитировано
0
Brazilian Journal of Health Review, Год журнала: 2024, Номер 7(4), С. e72060 - e72060
Опубликована: Авг. 21, 2024
Introdução: A pandemia de COVID-19 afetou gravemente pacientes com Lúpus Eritematoso Sistêmico (LES), que têm maior risco complicações devido a perturbações imunológicas e ao uso imunossupressores. Além aumentar vulnerabilidade à infecção, trouxe desafios no manejo do LES, incluindo o medicamentos impacto da autoimunidade desencadeada pelo vírus. Objetivo: avaliar em identificar fatores associados. Metodologia: Trata-se uma revisão integrativa na base dados PUBMED utilizando os descritores “SYSTEMIC LUPUS ERYTHEMATOSUS AND COVID-19’’ para artigos publicados entre 2020 2024. Resultados: foram identificados 828 artigos, dos quais 9 selecionados. taxa hospitalização variou 0,8% 80%, dependendo das metodologias. Foi relatada 30% hospitalização, três vezes LES comparado população geral. raça foi um fator significativo, não brancos apresentando risco. O hidroxicloroquina apresentou enquanto rituximabe aumentou hospitalização. SARS-CoV-2 pode ser gatilho mas estudos amostras pequenas, dificultando diagnóstico sintomas semelhantes. Pacientes apresentam trombocitopenia lesão renal associada gravidade doença. As taxas infecção por variaram 2,5% 82% Conclusão: COVID-19, variações significativas estudos. glicocorticoides ligado graves, exigindo cautela desses medicamentos. vacinas mRNA se mostraram eficazes, apesar hesitação vacinal, principalmente homens jovens. Disparidades acesso saúde afetaram resultados, minorias raciais enfrentando maiores mortalidade.
Процитировано
0
Archives of Clinical Infectious Diseases, Год журнала: 2023, Номер 18(5)
Опубликована: Дек. 6, 2023
Background: This study aimed to investigate the incidence and clinical characteristics of flare-ups in patients with systemic lupus erythematosus (SLE) following immunization inactivated SARS-CoV-2 vaccines. Methods: In this cross-sectional at Imam Hossein Hospital's Rheumatology Clinic (Iran), we investigated 72 SLE remission who received Sinopharm BIBP COVID-19 vaccine. Their post-vaccination status was monitored for 3 months using Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) checklist by an internal medicine specialist. Results: Fourteen (19.44%) experienced symptom after vaccination. The most common symptoms were arthritis (64.29%) skin rash (21.43%). Age, sex, organ involvement, treatment regimen did not significantly differ between those without recurrence (P > 0.05). second vaccine dose led more compared first (12.12% vs. 8.33%, P < 0.001). However, severity recurrence, measured SLEDAI-2K score = 0.763), interval from vaccination 0.075) 2 groups. Except patients, none participants required hospitalization, flare-up effectively managed prednisolone dosage adjustments. For these changed, steroid increased; one them admitted hospital, other on outpatient basis. Conclusions: low; mild require except 1 patient hospitalized rituximab due vasculitis flare. These findings highlight safety underscore importance close monitoring, especially dose.
Язык: Английский
Процитировано
1
Scientific Reports, Год журнала: 2022, Номер 12(1)
Опубликована: Авг. 12, 2022
Abstract In SLE, underlying immune dysregulation and immunosuppression may increase the susceptibility to COVID-19 impair humoral adaptive response. We aimed characterize infection, identifying severity risk factors, assessing presence of SARS-CoV-2 IgG antibodies analyzing cellular established a prospective cohort lupus patients estimate incidence compared reference general population. Data were collected via telephone interviews medical record review. measured cross-sectionally as part routine surveillance. Longitudinal changes in antibody titers immunological profile from convalescent evaluated at 6, 12 24 week after symptom onset. From studies, PBMCs extracted analyzed by flow cytometry gene expression analysis. included 725 patients, 29 with PCR-confirmed infection 16 COVID-19-like symptoms without PCR-testing. Of confirmed cases, 7 had severe disease, 8 required hospital admission (27.6%), 4 intensive care, 1 died. accumulated was higher patients. Health care workers anti-SSA/Ro52 positivity factors for susceptibility, hypocomplementemia severity. detected 8.33% Three fourths cases developed antibodies. High prednisone doses associated lack Antibody declined over time (39%). Convalescent onset displayed CD8 + T cell reduction predominant Th17 mild Th2 response, more pronounced disease. response analysis showed progressive sustained B memory cells decrease signaling. Lupus are new identified. able mount responses despite immunosuppressive therapy.
Язык: Английский
Процитировано
2
International Journal of Research in Medical Sciences, Год журнала: 2023, Номер 11(6), С. 2214 - 2236
Опубликована: Май 29, 2023
The purpose of this work was to analyse published data on rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and multiple sclerosis (MS) SARS-CoV-2 infection: susceptibility, post-infection autoimmune disease (AD) exacerbation, immunosuppressive therapies long COVID. Supported by PICO strategy, two independent reviewers conducted the research in PubMed/Medline database from January 2020 June 2022 included 16 articles RA, 25 MS 12 SLE. quality assessment studies performed using criteria National Institute Health. Patients with RA or SLE had increased susceptibility contracting SARS-CoV-2. It higher patients’ comorbidities. For MS, similar general population. Post-infection AD exacerbation occurred AR, an number hospitalisations deaths. Regarding therapies, use glucocorticoids (GC) associated a worsening infection. A more severe clinical picture anti-CD20 methylprednisolone MS. Considering COVID, patients risk complications opposite patients. There infection rheumatological diseases AR SLE, exacerbated age GC aggravated for antibodies use. In all there translated latter exception.
Язык: Английский
Процитировано
0
Опубликована: Янв. 1, 2023
Язык: Английский
Процитировано
0
Lupus, Год журнала: 2023, Номер 32(10), С. 1173 - 1178
Опубликована: Июль 20, 2023
Background COVID-19 pandemic was declared by WHO in March 2020. Severity of disease varied from asymptomatic to fatal infection. Severe found be associated with hyperinflammation syndrome. Systemic lupus erythematosus (SLE) is treated various immunosuppressive agents, intensity which depends on the severity disease. We aimed study characteristic SLE patients infected COVID-19. Methods 352 were included this observational cross-section conducted over a 30-month period beginning 24 th February 2020 (first COVID cases documented Oman) until end July 2022. Data retrieved electronic medical records and through questionnaire handed OPD or filled phone calls. Results 40.6% developed infection mean age 37 years maintaining their male female ratio as Majority both COVID-infected non-infected groups had activity zero. Sore throat cough present almost all patients. Other common symptoms myalgia/arthralgia (94%) followed fever. Significant difference between lung involvement. No noted two other parameters including regarding frequency medication. Conclusions This first Gulf Council Countries (GCCs). A significant uninfected seen whether involved no impact for DM, HTN, BMI, IHD, nephrites medication
Язык: Английский
Процитировано
0
Lupus Science & Medicine, Год журнала: 2023, Номер 10(2), С. e000966 - e000966
Опубликована: Окт. 1, 2023
To investigate the association of medication copayment and treatment adherence to hydroxychloroquine immunosuppressants for SLE. We conducted a retrospective analysis health claims data using Optum's de-identified Clinformatics Data Mart Database. Individuals with SLE continuously enrolled 180 days from 1 July 2010 31 December 2019 were included. Adherence was defined as proportion covered ≥80%. Copayment 30-day supply dichotomised high (≥$10) or low (<$10). examined between odds in multivariable-adjusted logistic regression models, including age, sex, race ethnicity, comorbidities, educational attainment household income. identified 12 510 individuals (age 54.2±15.5 years; 88.2% female sex), whom 9510 (76%) prescribed 1880 (15%) an additional immunosuppressant (azathioprine, methotrexate mycophenolate mofetil). Median (IQR) copayments $8 (4-10) hydroxychloroquine, $7 (2-10) azathioprine, (3-11) $10 (5-20) mofetil. High associated OR 0.61 (95% CI 0.55 0.68) 0.44 0.30 0.66) azathioprine 0.69 0.49 0.96) For methotrexate, not significant. In large, administrative database, we that reduced commonly medications Incorporating awareness burden its consequences into healthcare is essential promote optimal adherence.
Язык: Английский
Процитировано
0